Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 EV-to-EBIT is -8.01 as of Sep. 10, 2026. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 366 Biotechnology companies, SinoMab BioScience ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SinoMab BioScience's Enterprise Value for the quarter that ended in Dec. 2025 was €0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-22.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience EV-to-EBIT Related Terms
SinoMab BioScience EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4VF vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, SinoMab BioScience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's EV-to-EBIT falls into.
SinoMab BioScience's current Enterprise Value is €178.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-22.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (FRA:4VF) has a EV-to-EBIT of -8.01 as of Sep. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #999999 out of 366 companies in the Biotechnology industry.
Is SinoMab BioScience's EV-to-EBIT too high?
SinoMab BioScience's current EV-to-EBIT is -8.01. Based on the distribution chart, SinoMab BioScience ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #999999 out of 366 companies for EV-to-EBIT. This places SinoMab BioScience in the lower half of its industry. The industry median EV-to-EBIT is 15.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.59, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SinoMab BioScience and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current EV-to-EBIT is -8.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current EV-to-EBIT of -8.01. The current EV-to-EBIT is -8.01. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current EV-to-EBIT is -8.01 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
